Alterations in signal transducing molecule CD3ζ in patients with neplastic diseases

Archivum Immunologiae et Therapiae Experimentalis

Volumn 46, Issue 6, 1998, Pages 355-359

  Frydecka, Irena ^a,b   Kaczmarek, Paweł ^a   Boćko, Dorota ^b   Kosmaczewska, Agata ^b   Ciszak, Lidia ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

CD3 ; Neoplastic diseases

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

CANCER PATIENT; CYTOKINE PRODUCTION; HUMAN; IMMUNOREGULATION; NATURAL KILLER CELL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTIGENS, CD3; CYTOKINES; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0032418909     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. ANDERSON P., BLUE M. L., O'BRIEN C. and SCHLOSSMAN S. F. (1989): Monoclonal antibodies reactive with the T cell receptor ζ chain: production and characterization using new method. J. Immunol., 143, 1899-1904.
2. ANDERSON P., CALIGIURI M., O'BRIEN C., MANLEY T., RITZ J., STUART F. and SCHLOSSMAN S. F. (1990): Fey receptor type III (CD16) is included in the ζ NK receptor complex expressed by human natural killer cells. Proc. Natl. Acad. Sci. USA, 87, 2274-2278.
3. AOE T., OKAMOTO Y. and SAITO T. (1995): Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med., 181, 1881-1886.
4. BUGGINS A. G. S., HIRST W. J. R., PALICA A. and MUFTI J. (1988): Variable expression of CD3-ζ and associated protein kinases in lymphocytes from patients with myeloid malignancies. Br. J. Haematol., 100, 784-792.
5. FARACE F., ANGEVIN E., VANDERPLANCKE J., ESCUDIER B. and TRIEBEL F. (1994): The decreased expression of CD3ζ chains in cancer patients is not reversed by IL-2 administration. Int. J. Cancer, 59, 752-755.
6. FINKE J. H., ZEA A. H., STANLEY J., LONGO D. L., MIZODUCHI H., TUBES R. R., WILTROUT R. H., O'SHEA J. J., KUDOH S., KLEIN E., BUKOWSKI R. M. and OCHOA A. C. (1993): Loss of T-cell receptor ζ chain and p56 lck in T-cell infiltrating human renal cell carcinoma. Cancer Res., 53, 5613-5616.
7. FRANK S., NIKLINSKA B., ORLOFF D., MERCFP M., ASHWELL J. and KLAUSNER R. (1990): Structural mutations of the T cell receptor zeta chain and its role in T cell activation. Science, 249, 174-177.
8. FU E. J., ARCA M. J., HAIN J. M., KRINOCK R., RADO J., CAMERON M. J., CHANG A. E. and SONDAK V. K. (1997): Tumor-induced suppression of antitumor reactivity and depression of TCR zeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway. J. Immunother., 20, 111-122.
9. FUJI T., IGARASHI T. and KISHIMOTO S. (1987): Significance of suppressor macrophages for immune surveillance of tumor bearing mice. J. Natl. Cancer Inst., 78, 509-517.
10. GEISLER C., KUHLMANN J. and RUBIN B. (1989): Assembly, intracellular processing and expression at the cell surface of the human αβ T cell receptor/CD3 complex: function of the CD3-zeta chain. J. Immunol., 143, 4069-4077.
11. GUNJI Y., HORI S., AOE T., ASANO T., OCHIAI T., ISONO K. and SAITO T. (1994): High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn. J. Cancer Res., 85, 1189-1192.
12. HANSSON M., ASEA A., ERSSON U., HERMODSSON S. and HELLSTRAND K. (1996): Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol., 156, 42-47.
13. HELLSTRAND K., ASEA A., DAHLGREN C. and HERMODSSON S. (1994): Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J. Immunol., 153, 4940-4947.
14. INVING B. A. and WEISS A. (1991): The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell, 64, 891-901.
15. KONO K., RESSING M. E., BRANDT R. M. P., MELIEF C. J. M., POTKUL R. K., ANDERSSON B., PETERSSON M., KAST W. M. and KIESSLING R. (1996): Decreased expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res., 2, 1825-1828.
16. KONO K., SALAZAR F., PETERSSON M., HANSSON M., MASUCCI G., WASSERMAN K., NAKAZAWA T., ANDERSON P. and KIESSLING R. (1996): Hydrogene peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T-cell and NK-cell mediated cytotoxicity. Eur. J. Immunol., 10, 199-215.
17. LAI P., RABINOWICH H., CROWLEY-NOWICK P. A., BELL M. C., MANTOVANI G. and WHITESIDE T. L. (1996): Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res., 2, 161-173.
18. MALISSEN M., GILLETA A. and ROCHA B. (1993): T cell development in mice lacking the CD3-zeta/zeta gene. EMBO J., 12, 4347-4355.
19. MATSUDA M., PETERSSON M., LENKEI R., TAUPIN J. L., MAGNUSSON I., MELLSTEDT H., ANDERSON P. and KIESSLING R. (1995): Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: correlation with stage of the disease. Int. J. Cancer, 61, 765-772.
20. MASSAIA M., ATTISANO C., BEGGIATO E., BIANCHI A. and PILERI A. (1994): Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br. J. Haematol., 88, 886-888.
21. MIZOGUCHI H., O'SHEA J. J., LONGO D. L., LOEFFER C. M., MCVICAR D. W. and OCHOA A. C. (1992): Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science, 258, 1795-1798.
22. MULDER W. M., BLOEMENA E., STUKART M. J., KUMMER J. A., WAGSTAFF J. and SHEPER R. J. (1997): T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut, 40, 113-119.
23. NAKAGOMI H., PETERSSON M., MAGNUSSON I., JUHLIN C., MATSUDA M., MELLSTEDT H., TAUPIN J. L., VIVIER E., ANDERSON P. and KIESSLING R. (1993): Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53, 5610-1612.
24. OCHOA A. C. and LONGO D. L. (1995): Alteration of signal transduction in T lymphocytes cells from cancer patients. In DEVITA V. T. JR., HELLMAN S. and ROSENVERG S. A. (eds.): Important advances in oncology 1995. Lippincott, Philadelphia, 43-54.
25. OHNO H., AOE T., TAKI S., KITAMURA D., ISHIDA Y., RAJEWSKY K. and SAITO T. (1993): Developmental and functional impairment of T cells in mice lacking CD3 zeta chains. EMBO J., 12, 4357-4366.
26. RABINOWICH H., BANKS M., REICHERT T. E., LOGAN T. F., KIRKWOOD J. M. and WHITESIDE T. L. (1996): Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin-2 therapy. Clin. Cancer Res., 2, 1263-1274.
27. RENNER C., OHNESORGE S., HELD G., BAUER S., JUNG W., PFITZENMEIER J. P. and PFEUNDSCHUH M. (1996): T cells from patients with Hodgkin's diseases have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood, 88, 236-241.
28. ROSSI E., MATUTES E., MORILLA R., OWUSU-ANKOMAH K., HEFFERNAN A. M. and CATOVSKY D. (1996): Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia, 10, 494-497.
29. RUDD C. E., JANSSEN O., CAI YU. C., DA SILVA A. J., RAAB M. and PRASAD K. V. (1994): Two step TCRzeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol. Today, 15, 225-234.
30. SALVADORI S., GANSBACHER B. and ZIER K. (1994): Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol., 53, 5176-5183.
31. SHORES E. W. and LOVE P. E. (1997): TCR zeta chain in T cell development and selection. Curr. Opin. Immunol., 9, 380-388.
32. SUSSMAN J. J., BONIFACINO J. S., LIPPINCOTT-SCHWARTZ J., WEISSMAN A. M., SAITO T., KLAUSNER R. D. and ASHWELL N. J. D. (1988): Failure to sunthesize the T-cell CD3-zeta chain: structure and function of partial T receptor complex. Cell, 52, 85-95.
33. TARTOUR E., LATOUR S., MATHIOT C., THIOUNN N., MOSSERI V., JOYEUX I., D'ENGHIEN C. D., LEE R., DEBRE B. and FRIDMAN W. H. (1995): Variable expression of CD3 zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int. J. Cancer, 63, 205-212.
34. WEISS A. and LITTMAN D. R. (1994): Signal transduction by lymphocyte antigen receptor. Cell, 76, 263-274.
35. WEISSMAN A. M. (1994): The T cell-antigen receptor. A multisubunit signaling complex. Chem. Immunol., 59, 1-18.
36. ZEA A. H., CURTI B. D., LONGO C. D., ALVORD W. G., STROBL S. L., MIZOGUCHIL H., CREEKMORE S. P., O'SHEA J. J., POWERS G. C., URBA W. J. and OCHOA A. C. (1995): Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res., 1, 1327-1335.